DR. STEVEN E ARTANDI, M.D. Osteopathic Medicine in Palo Alto, CA
License number
California G86580
Category
Osteopathic Medicine
Type
Hematology
Address
Address
269 Campus Dr Ccsr Rm. 1155, Palo Alto, CA 94305
Phone
(650) 736-0975 (650) 736-0974 (Fax)
Professional information
Steven Edward Artandi, Stanford CA
Specialties:
Internal Medicine, Hematology, Medical Oncology
Work:
Stanford University 300 Pasteur Dr, Stanford, CA 94305Stanford Hospital and Clinics 300 Pasteur Dr, Palo Alto, CA 94304
Education:
Columbia University (1995)
Dr. Steven E Artandi, Stanford CA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
STANFORD COMPREHENSIVE CANCER CENTER AT STANFORD UNIVERSITY MEDICAL CENTER 269 Campus Dr, Stanford 94305 (650) 725-5447 (Phone), (650) 725-1420 (Fax)
Certifications:
Internal Medicine, 1998, Medical Oncology, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
STANFORD COMPREHENSIVE CANCER CENTER AT STANFORD UNIVERSITY MEDICAL CENTER 269 Campus Dr, Stanford 94305 Stanford Hospital and Clinics 300 Pasteur Dr, Stanford 94305
Education:
Medical School Columbia University / College of Physicians And Surgeons Graduated: 1994 Massachusetts General Hospital Dana-Farber Cancer Institute
Steven E Artandi, Palo Alto CA
Specialties:
Hematologist
Address:
269 Campus Dr, Palo Alto, CA 94305
Education:
Columbia University, College of Physicians and Surgeons - Doctor of Medicine Dana-Farber Cancer Institute - Fellowship - Oncology (Internal Medicine) Massachusetts General Hospital - Residency - Internal Medicine
Methods And Compositions For Cell Activation
US Patent:
2006005, Mar 9, 2006
Filed:
Aug 4, 2005
Appl. No.:
11/198908
Inventors:
Steven Artandi - Stanford CA, US Kavita Sarin - Mountain View CA, US Maja Artandi - Portola Valley CA, US
International Classification:
A61K 48/00, C12N 15/87
US Classification:
514044000, 435455000
Abstract:
Methods and compositions for activating a cell are provided. In practicing the subject methods, a cell including a coding sequence for either a telomerase reverse transcriptase (TERT) or a telomerase RNA component (TERC) is activated by conditionally increasing expression of the coding sequence. Also provided are transgenic animals and systems for practicing the subject methods.